

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
 NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
 NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
 IPC reform
 NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
 USPAT2
 NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDb, and IFICDB
 NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
 INPADOC
 NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
 NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
 NEWS 13 JAN 30 Saved answer limit increased
 NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
 added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:37:50 ON 16 FEB 2006

=> fil reg

10727997RTR

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom

Generic attributes :

9:

Number of Hetero Atoms : less than 2

Type of Ring System : Polycyclic

Element Count :

Node 9: Limited

O,O1


C,C8

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:39:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1354 TO ITERATE

100.0% PROCESSED 1354 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 24873 TO 29287

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:39:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 27596 TO ITERATE

100.0% PROCESSED 27596 ITERATIONS

18 ANSWERS

SEARCH TIME: 00.00.01

L3 18 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

10727997RTR

FULL ESTIMATED COST

167.38

167.59

FILE 'HCAPLUS' ENTERED AT 13:39:17 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 15 Feb 2006 (20060215/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 1 L3

=> d ed abs ibib hitstr

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 18 Jun 2004
 GI



AB Title compds. [I: X = O, S; G = C:(NR3)NR2L2NR4R5, C(NR3)NR2L3R14, etc.; L2 = (substituted) (interrupted) alkylidene which may form part of a 3-7 membered ring; L3 = bond, L2; R1 = H, aliphatic; R2 = H, aliphatic, aryl, aralkyl, electron pair; R3 = H, aliphatic, aryl, aralkyl; R4 = H, aliphatic, aliphaticcarbonyl, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.; R5 = H, aliphatic; R4R5N = (substituted) mono-, bi- or tricyclic ring; A = atoms to form a (substituted) 5-membered heteroaryl, 6-membered aryl ring; R14 = H, aliphatic, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl; NR3R14 = (substituted) mono-, bi-, or tricyclic (aromatic) heterocyclyl; Q = (substituted) (interrupted) alkylidene; Ph ring attached to Q may be substituted], were prepared as melanocortin MC4 receptor antagonists (no data). Thus, 1-[2-[(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]-2-methylisothiourea, Et3N, and 1-(3-aminopropyl)-2-pipecoline were refluxed in xylene to give N-[2-[(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]-N'-[3-(2-methylpiperidin-1-yl)propyl]guanidine as the bisformate salt.


ACCESSION NUMBER: 2004:493667 HCAPLUS
 DOCUMENT NUMBER: 141:54200
 TITLE: Preparation of acrolylguanidines as melanocortin MC4 receptor antagonists.
 INVENTOR(S): Vos, Tricia J.; Patane, Michael; Solomon, Michael E.; Blackburn, Christopher; Danca, Mihaela D.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 151 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050610	A2	20040617	WO 2003-US38369	20031204
WO 2004050610	A3	20040826		

V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2508914 A1 20040729 US 2003-727997 20031204
 US 2004147746 AA 20040617 CA 2003-2508914 20031204
 EP 1590338 A2 20051102 EP 2003-812495 20031204
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPL. INFO.: US 2002-430789P P 20021204
 WO 2003-US38369 W 20031204

OTHER SOURCE(S): MARPAT 141:54200
 IT 705978-22-9P 705978-23-0P 705978-27-4P
 705978-28-5P 705978-32-1P 705978-37-6P
 705978-41-2P 705978-42-3P 705978-47-8P
 705978-48-9P 705978-49-0P 705978-51-4P
 705978-71-8P 705978-72-9P 705978-80-9P
 705978-81-0P 705978-95-6P 705978-82-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 705978-22-9 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-23-0 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-2-methyl-7-benzofuranyl)ethyl]-N-[[[4-(diethylamino)-1,1-dimethylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-27-4 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[[5-(1-piperidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-28-5 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[[5-(1-pyrrolidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-32-1 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[3-pyrrolidinylamino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-37-6 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[imino[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-41-2 HCAPLUS
 CN Benzamide, 2-[2-[(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[imino[[4-(piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-42-3 HCAPLUS
 CN Benzamide, 2-[2-[(5-cyano-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[[4-(piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-47-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-48-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[[4-(pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-49-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[[4-(piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-80-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705978-81-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-95-6 HCAPLUS
 CN 4-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-51-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-71-8 HCAPLUS
 CN 4-Piperidinepropanoic acid, beta-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)




RN 705978-72-9 HCAPLUS
 CN 4-Piperidineacetic acid, alpha-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705979-82-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[[3-(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.64	175.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'REGISTRY' ENTERED AT 13:39:50 ON 16 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
 DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> log H

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.08	178.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 13:43:50 ON 16 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
 SESSION RESUMED IN FILE 'REGISTRY' AT 14:28:43 ON 16 FEB 2006
 FILE 'REGISTRY' ENTERED AT 14:28:43 ON 16 FEB 2006
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.08	178.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.52	178.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'REGISTRY' ENTERED AT 14:29:01 ON 16 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
 DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10727997RTRBphenyl.str



chain nodes :

1 2 3 4 5 6 7 8

ring nodes :

9 10 11 12 13 14

chain bonds :

1-2 1-8 2-3 2-5 3-4 4-6 4-7 8-9

ring bonds :

9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-8 2-3 2-5 3-4 4-6 4-7 8-9

exact bonds :

1-2

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14

Match level :


1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 14:29:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1072 TO ITERATE

100.0% PROCESSED 1072 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19476 TO 23404
PROJECTED ANSWERS: 44 TO 476

L6 13 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 14:29:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22281 TO ITERATE

100.0% PROCESSED 22281 ITERATIONS 226 ANSWERS
SEARCH TIME: 00.00.01

L7 226 SEA SSS FUL L5

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	166.94	345.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'HCAPLUS' ENTERED AT 14:29:46 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 15 Feb 2006 (20060215/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


10727997RTR

=> s 17
L8


12 L7

=> d ed abs ibib hitstr 1-12


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-50-0 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[1-phenylethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-51-1 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[2-thienylethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-52-2 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-pyridinylethyl]amino]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705977-53-3 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[1-phenyl-2-(1-pyrrolidinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-54-4 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-chlorophenyl]methyl][2-(1-pyrrolidinyl)ethyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705977-55-5 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-56-6 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-57-7 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-58-8 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(4-methyl-1-piperazinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-59-9 HCAPLUS
 CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-79-3 HCAPLUS
 CN Benzamide, 3-fluoro-N-[[3-(1-pyrrolidinyl)propyl]amino]methyl-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-80-6 HCAPLUS
 CN Benzamide, 3-fluoro-N-[[3-(4-morpholinyl)propyl]amino]methyl-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-81-7 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705977-85-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino](methylamino)methylene]- (9CI) (CA INDEX NAME)




RN 705977-86-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-82-8 HCAPLUS
 CN Benzamide, 2-[2-(2-bromo-5-chlorophenyl)ethyl]-3-fluoro-N-[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-83-9 HCAPLUS
 CN Benzamide, 2-[2-(2-bromo-5-chlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-84-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-87-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino](methylamino)methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-88-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-89-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-methylethyl]amino]([3-(2-methyl-1-piperidinyl)propyl]amino)methylene]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705977-90-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino] (1-methylethyl)amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-91-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino] (1-methylethyl)amino]methylene]- (9CI) (CA INDEX NAME)




L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705977-96-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)cyclohexyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-97-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)cyclopentyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-98-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-3-oxobutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 705977-92-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino] (phenylamino)methylene]- (9CI) (CA INDEX NAME)



RN 705977-93-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino] (phenylamino)methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-94-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(2-methyl-1-piperidinyl)propyl]amino] (phenylamino)methylene]- (9CI) (CA INDEX NAME)




RN 705977-95-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino] (phenylamino)methylene]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-02-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino] (methylamino)methylene]- (9CI) (CA INDEX NAME)




RN 705978-03-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)cyclohexyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-11-6 HCAPLUS
 CN Proline, 1-[3-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]propyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-12-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705978-13-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-oxo-3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 705978-14-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(cyclohexylamino)propyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-15-0 HCAPLUS
 CN Benzamide, N-[[[1-azabicyclo[2.2.2]oct-3-ylamino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-16-1 HCAPLUS
 CN 1-Pyrrolidinepentanoic acid, alpha-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)




RN 705978-17-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(dimethylamino)cyclohexyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

705978-18-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-oxo-3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 705978-20-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)-2,2-difluoropropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-21-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)-2-hydroxypropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-22-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino]iminoethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-23-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methyl-7-benzofuranyl)ethyl]-N-[[4-(diethylamino)-1,1-dimethylbutyl]amino]iminoethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-24-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[4-(diethylamino)-1-methylbutyl]amino]iminoethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-27-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[5-(1-piperidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-28-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[5-(1-pyrrolidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-29-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[5-(1-pyrrolidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-25-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-26-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [[(1R)-1-phenylethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-30-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-[[methyl[(1R)-1-phenylethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-31-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[3-(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-32-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[3-(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-33-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-[[4-(methylsulfonyl)phenyl]methyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-34-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-[[4-(1-methylethyl)phenyl]methyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-35-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-[[2-(dimethylamino)ethyl]phenyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[[4-[[1-pyrrolidinyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-38-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-ethoxy-N-[[4-[[1-pyrrolidinyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-39-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[4-[[6-methyl-6-azabicyclo[3.1.1]hept-3-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-40-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[4-[[6-methyl-6-azabicyclo[3.1.1]hept-3-yl]amino]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-36-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-[[4-(methylsulfonyl)phenyl]methyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 705978-37-6 HCAPLUS


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[[4-[[1-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-41-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[[4-[[1-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-42-3 HCAPLUS
 CN Benzamide, 2-[2-(5-cyano-7-benzofuranyl)ethyl]-3-fluoro-N-[[4-[[1-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-43-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[4-[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-44-5 HCAPLUS
 CN Benzamide, N-[(trans-4-aminocyclohexyl)amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 705978-45-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino(3-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-46-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-50-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-51-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-52-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-47-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino(2-(1H-indol-3-yl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-48-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-49-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-53-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-54-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 705978-55-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[[2-(2-piperidinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-56-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-57-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[1-(phenylmethyl)-3-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-58-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-62-7 HCAPLUS
 CN Benzamide, N-[[[1-(3-(aminomethyl)phenyl)methyl]amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705978-63-8 HCAPLUS
 CN Benzamide, N-[[[trans-4-[bis(cyclopropylmethyl)amino]cyclohexyl]amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 705978-64-9 HCAPLUS
 CN Benzamide, N-[[[trans-4-[bis(cyclopentylmethyl)amino]cyclohexyl]amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-59-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[trans-4-(hydroxycyclohexyl)amino]iminomethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 705978-60-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[2-(1-piperazinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-61-6 HCAPLUS
 CN Benzamide, N-[[[trans-4-(aminocyclohexyl)amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-65-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopentylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-66-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705978-67-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[1-(1-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-68-3 HCAPLUS
 CN 4-Piperidinepropanoic acid, β-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]-1-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 705978-69-4 HCAPLUS
 CN 4-Piperidineacetic acid, α-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)




RN 705978-70-7 HCAPLUS
 CN 4-Piperidinepropanoic acid, β-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-74-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-76-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-77-4 HCAPLUS
 CN Cyclopropanecarboxylic acid, 2-[[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]methyl]-1-piperidinylmethyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-71-8 HCAPLUS
 CN 4-Piperidinepropanoic acid, β-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)




RN 705978-72-9 HCAPLUS
 CN 4-Piperidineacetic acid, α-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)




RN 705978-73-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-78-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(4-methylpropylamino)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-79-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(1-(2-methylpropyl)-4-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-80-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-81-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-82-1 HCAPLUS
 CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 705978-83-2 HCAPLUS
 CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


RN 705978-87-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-(1-oxo-2,8-diazaspiro[4.5]dec-8-yl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-88-7 HCAPLUS
 CN 2H-Pyrrolium, 2-(aminocarbonyl)-1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-84-3 HCAPLUS
 CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 705978-85-4 HCAPLUS
 CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-86-5 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2S)- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 705978-89-8 HCAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-90-1 HCAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 705978-91-2 HCAPLUS
 CN 4-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 705978-92-3 HCAPLUS
 CN 2-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 705978-93-4 HCAPLUS
 CN 2-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 705978-96-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-(1-piperidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-97-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-98-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[3R]-1-(phenylmethyl)-3-pyrrolidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-99-0 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705978-94-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-(1-piperidinyl)carbonyl]-1-piperidinyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-95-6 HCAPLUS
 CN 4-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 705979-00-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(3,4-dihydro-2(1H)-isoquinolinyl)butyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705979-01-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-(octahydro-2(1H)-isoquinolinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705979-02-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[methyl(phenylmethyl)amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 705979-03-9 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-methyl(1S)-1-phenylethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705979-04-0 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[4-methyl(2-(2-pyridinyl)ethyl)amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705979-05-1 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-ethyl(4-pyridinylmethyl)amino]butyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-06-2 HCAPLUS

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705979-09-5 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(3-hydroxy-1-pyrrolidinyl)butyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705979-10-8 HCAPLUS

CN Benzamide, N-[[[4-(3-(acetylmethylamino)-1-pyrrolidinyl)butyl]amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(3-(dimethylamino)-1-pyrrolidinyl)butyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-07-3 HCAPLUS

CN Proline, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 705979-08-4 HCAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 705979-11-9 HCAPLUS


CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-12-0 HCAPLUS

CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(2-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705979-13-1 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(3,5-dimethoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-14-2 HCAPLUS
 CN Benzamide, 2-[2-(3,4-dichlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-15-3 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705979-19-7 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(4-(trifluoromethoxy)phenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 705979-20-0 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-31-3 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 705977-44-2
 CMF C26 H34 Br F N4 O2


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705979-16-4 HCAPLUS
 CN Benzamide, 2-[2-(3-cyanophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-17-5 HCAPLUS
 CN Benzamide, 2-[2-(4-bromophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705979-18-6 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(4-(1,1-dimethylethyl)phenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-32-4 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[butylamino]iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-45-3
 CMF C21 H25 Br F N3 O2



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 705979-33-5 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[2-methylpropyl]amino]methyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-46-4
 CMF C21 H25 Br F N3 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-34-6 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[cyclopentylamino]iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CH 1
CRN 705977-47-5
CHF C22 H25 Br F N3 O2




CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-35-7 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[2-(1-pyrrolidinyl)ethyl]amino]methyl]benzamide (1:1) (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-37-9 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[1-phenylethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 705979-38-0 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[2-(thienylmethyl)amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CH 1
CRN 705977-51-1
CHF C22 H21 Br F N3 O2 S

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CH 1
CRN 705977-48-6
CHF C23 H28 Br F N4 O2




CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-36-8 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[(2-cyclohexylethyl)amino]iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CH 1
CRN 705977-49-7
CHF C25 H31 Br F N3 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-39-1 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[3-pyridinylmethyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CH 1
CRN 705977-52-2
CHF C23 H22 Br F N4 O2




CH 2
CRN 64-18-6
CHF C H2 O2

O=CH-OH

RN 705979-40-4 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[1-phenyl-2-(1-pyrrolidinyl)ethyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CH 1

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 705977-53-3
CMF C29 H32 Br F N4 O2CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-41-5 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-chlorophenyl)methyl][2-(1-pyrrolidinyl)ethyl]amino]iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-54-4
CMF C30 H33 Br Cl F N4 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-43-7 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino]iminomethyl]benzamide (1:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-56-6
CMF C23 H25 Br F N5 O2CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-44-8 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluorobenzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-57-7
CMF C26 H36 Br F N4 O2


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-42-6 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(4-morpholinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-55-5
CMF C24 H30 Br F N4 O3

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 705979-45-9 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(4-methyl-1-piperazinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-58-8
CMF C25 H33 Br F N5 O2CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 705979-46-0 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1-piperidinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 705977-59-9
CMF C25 H32 Br F N4 O2CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-66-4 HCAPLUS
CN Formic acid, compd. with 3-fluoro-N-[[[4-(1-pyrrolidinyl)propyl]amino]methyl]-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-79-3
CMF C27 H31 F N4 OCM 2
CRN 64-18-6
CMF C H2 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 705979-69-7 HCAPLUS
CN Formic acid, compd. with 2-[(2-bromo-5-chlorophenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-82-8
CMF C25 H31 Br Cl F N4 OCM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-70-0 HCAPLUS
CN Formic acid, compd. with 2-[(2-bromo-5-chlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluorobenzamide (2:1)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


O=CH-OH

RN 705979-67-5 HCAPLUS
CN Formic acid, compd. with 3-fluoro-N-[[[4-(4-morpholinyl)propyl]amino]methyl]-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-80-6
CMF C27 H31 F N4 O2CM 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-68-6 HCAPLUS
CN Formic acid, compd. with N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)CM 1
CRN 705977-81-7
CMF C29 H37 F N4 O


L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1
CRN 705977-83-9
CMF C25 H33 Br Cl F N4 OCM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 705979-72-2 HCAPLUS
CN Benzamide, 2-[(2-(5-bromo-2-methoxyphenyl)ethyl)-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]methylene]-, dihydrochloride (9CI) (CA INDEX NAME)RN 705979-73-3 HCAPLUS
CN Benzamide, 2-[(2-(5-bromo-2-methoxyphenyl)ethyl)-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methylene]-, dihydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

RN 705979-74-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(methylamino)[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]methylene]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705979-75-5 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(1-methylethylamino)[(3-(2-methyl-1-piperidinyl)propyl)amino]methylene]benzamide (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 705977-89-5
 CMF C29 H40 Br F N4 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [[3-(1H-imidazol-1-yl)propyl]amino][1-methylethyl]amino]methylene]benzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-91-9
 CMF C26 H31 Br F N5 O2



CH 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 705979-78-8 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1-methyl-2-pyrrolidinyl)ethyl]amino](phenylamino)methylene]benzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-92-0
 CMF C30 H34 Br F N4 O2

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2


CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-76-6 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino][1-methylethyl]amino]methylene]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-90-8
 CMF C29 H42 Br F N4 O2




CH 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-77-7 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CH 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 705979-79-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino](phenylamino)methylene]-3-fluoro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 705979-80-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(2-methyl-1-piperidinyl)propyl]amino](phenylamino)methylene]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705979-81-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino]methylene-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl

RN 705979-82-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[3-(4-morpholinyl)propyl]amino]methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 23 Nov 2001
 GI



I




II

AB Bisacylguanidines I [one of R1, R2, R3, R4 or R5 = CON:C(NH2)2, CH:OMeCON:C(NH2)2 and one of R6, R7, R8, R9 or R10 = CON:C(NH2)2, CH:OMeCON:C(NH2)2; the other R1 - R10 = H, A, CH, F, Cl, Br, I, SA, OA, SO2A, OH, NH2, NHA, NA2, COA, (un)substituted Ph, CH2Ph, OPh, N-, S-, O-containing heterocycle; X = S, SO2, (CH2)n, CO, O, OCH2; A = Cl-8-alkyl; n = 1 - 3] and their physiol. harmless salts and/or solvates, with cardioprotective characteristics and works as inhibitors of the cellular Na+/H+ antiporters of the Subtyp 1 are described. Thus, N-[3-[2-(3-guanidinocarbonylphenyl)ethyl]benzoyl]guanidine dihydrochloride (II-HCl), was prepared from 3-[2-(3-carboxyphenyl)ethyl]benzoic acid and Boc-guanidine in 1-methyl-2-pyrrolidone containing 2-chloro-1-methylpyridinium iodide and Et2NCHMe2, followed by hydrolysis with aqueous HCl. Formulations for use in injections, suppositories, solns., tablets, capsules and ampules are given.


ACCESSION NUMBER: 2001:850646 HCAPLUS
 DOCUMENT NUMBER: 135:371527
 TITLE: Preparation of bisacylguanidine with cardioprotective activity
 INVENTOR(S): Gericke, Rolf; Beier, Norbert
 PATENT ASSIGNER(S): Merck Patent G.m.b.H., Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10024319	A1	20011122	DE 2000-10024319	20000517
WO 2001087829	A1	20011122	WO 2001-EP4425	20010419
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,			




● 2 HCl

L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPL. INFO.: DE 2000-10024319 A 20000517
 OTHER SOURCE(S): CASREACT 135:371527; MARPAT 135:371527
 IT 374681-40-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of cardioprotective bisacylguanidines that work as inhibitors of the cellular Na+/H+ antiporters)
 RN 374681-40-0 HCAPLUS
 CN Carbamic acid, [1,2-ethanediy]bis(3,1-phenylenecarbonyliminocarbonimidoyl)bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 374681-41-1P 374681-43-3P 374681-44-4P
 374681-45-5P 374681-47-7P 374681-76-2P
 374681-77-3P 374681-78-4P 374681-79-5P
 374681-80-8P 374681-81-9P 374681-84-2P
 374682-08-3P, N-[3-[2-(3-Guanidinocarbonylphenyl)ethyl]benzoyl]guanidine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cardioprotective bisacylguanidines that work as inhibitors of the cellular Na+/H+ antiporters)
 RN 374681-41-1 HCAPLUS
 CN Benzamide, 3,3'-(1,2-ethanediy)bis(N-(aminoinomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 374681-43-3 HCAPLUS
 CN Benamide, N-(aminoiminomethyl)-3-[2-[[[(aminoiminomethyl)amino]carbonyl]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-44-4 HCAPLUS
 CN Benamide, N-(aminoiminomethyl)-2-[2-3-[[[(aminoiminomethyl)amino]carbonyl]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-45-5 HCAPLUS
 CN Benamide, N-(aminoiminomethyl)-2-[2-4-[[[(aminoiminomethyl)amino]carbonyl]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benamide, N-(aminoiminomethyl)-3-[4-[[[(aminoiminomethyl)amino]carbonyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

RN 374681-79-5 HCAPLUS
 CN Benamide, 4,4'-carbonylbis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 374681-80-8 HCAPLUS
 CN Benamide, N-(aminoiminomethyl)-2-[[4-[[[(aminoiminomethyl)amino]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-81-9 HCAPLUS
 CN Benamide, N-(aminoiminomethyl)-2-[3-[[[(aminoiminomethyl)amino]carbonyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 374681-47-7 HCAPLUS
 CN Benamide, 2,2'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-76-2 HCAPLUS
 CN Benamide, 4,4'-methylenebis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 374681-77-3 HCAPLUS
 CN Benamide, 3,3'-methylenebis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-78-4 HCAPLUS


L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 374681-84-2 HCAPLUS
 CN Benamide, 2,2'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-84-2 HCAPLUS
 CN Benamide, 2,2'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374682-08-3 HCAPLUS
 CN Benamide, 3,3'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 30 Jul 1999
 GI




AB Title compds. [I: n = 1-5; X = N, CR5; R5 = H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl, heteroaryl; R1-R4 = H, SH, OH, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, heteroaryloxy, alkyl, aryl, cycloalkyl, cycloalkenyl, amino, arylsulfonylamino, acyl, etc.], were prepared for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia (no data). Thus, trans-4-methylcinnamic acid in THF was treated with CH2N2 in Et2O to give 90% Me ester. The latter was stirred with guanidine in DMF to give 75% trans-N-(aminoiminomethyl)-2-(4-methylphenyl)cyclopropanecarboxamide.

ACCESSION NUMBER: 1999:468414 HCAPLUS
 DOCUMENT NUMBER: 131:102102
 TITLE: Preparation of acylguanidines as sodium/proton exchange inhibitors.
 INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; Atwal, Karnail S.; Dugar, Sundeep
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 139 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933460	A1	19990708	WO 1998-US25829	19981204
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, CA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316352	A1	19990719	CA 1998-2316352	19981204
AU 9917119	B2	20030313	AU 1999-17119	19981204
AU 758065	A1	20001011	EP 1998-961926	19981204
EP 1041980	B1	20050223		
EP 1041980				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001527042	T2	20011225	JP 2000-526217	19981204
AT 289509	E	20050315	AT 1998-961926	19981204
ES 2236965	T3	20050716	ES 1998-961926	19981204
ZA 9811786	A	20000622	ZA 1998-11786	19981222

L8 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 08 Nov 1997
 GI



AB The title compds. [I: R1 = R6C(O) (wherein R6 = Cl-8 alkyl, Cl-8 perfluoroalkyl, C3-8 alkenyl, etc.); R2 = H, halo, OH, etc.; R3 = R1 or R2; R4, R5 = R2] and their salts, useful for treating arrhythmias, treating or preventing diseases caused by ischemic conditions, for diagnosing hypertension and proliferative disorders, and treating myocardial infarction, angina pectoris, ischemic conditions of the heart, of the peripheral and central nervous systems, or the peripheral organs and limbs, of stroke and of conditions of shock, were prepared. Thus, Fries displacement of 4-acetoxycinnamic acid with AICl3 followed by reaction of the resulting 3-acetyl-4-hydroxybenzoic acid with carbonyldiimidazole and guanidine afforded I [R1 = MeCO; R2 = OH; R3-R5 = H] which showed IC50 of 2.0x10-6 M/L against Na+/H+ exchange.

ACCESSION NUMBER: 1997:705845 HCAPLUS
 DOCUMENT NUMBER: 127:358717
 TITLE: Preparation of substituted benzoylguanidines as diagnostic agent for inhibiting the Na+/H+ exchanger and diagnosing hypertension and proliferative disorders
 INVENTOR(S): Schwark, Jan-Robert; Kleemann, Heinz-Werner; Lang, Hans-Jochen; Weichert, Andreas; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 252,786, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5679712	A	19971021	US 1995-459966	19950602
IL 109887	A1	19980222	IL 1994-109887	19940603
DE 4441880	A1	19960530	DE 1994-4441880	19941124
US 5849775	A	19981215	US 1997-886037	19970630
PRIORITY APPL. INFO.:				
			US 1994-252786	B2 19940602
			DE 1994-4441880	19941124
			DE 1993-4318756	A 19930605
			US 1995-459966	A 19950602

OTHER SOURCE(S): MARPAT 127:358717
 IT 198477-63-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted benzoylguanidines as diagnostic agent for inhibiting the Na+/H+ exchanger and diagnosing hypertension and

L8 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PRIORITY APPL. INFO.: US 1997-68790P P 19971224
 US 1998-73740P P 19980205
 WO 1998-US25829 W 19981204


OTHER SOURCE(S): MARPAT 131:102102
 IT 230641-57-3P 230641-58-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of acylguanidines as sodium/proton exchange inhibitors)
 RN 230641-57-3 HCAPLUS
 CN Cyclopropanecarboxamide, N-(aminoiminomethyl)-2-(phenylmethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 230641-58-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-(aminoiminomethyl)-2-(phenylmethyl)-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 proliferative disorders)
 RN 198477-63-3 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-benzoyl-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

L8 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 25 Jun 1996
 GI




AB Guanidine derivs. I [R1 = H, hydroxyalkyl, protected hydroxyalkyl, acylalkoxy, acylalkenyl, acyl; R2 = aralkenyl disubstituted aryl, (un)substituted indenyl, indenyl, dihydrobenzocycloheptenyl, di- to decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl or heterobicyclic, alkylthienyl, mono- or dihalothienyl, haloalkylthienyl, acylthienyl, haloalkyl, haloalkylfuryl] and their pharmaceutically acceptable salts are claimed. The compds. are strong inhibitors of Na⁺/H⁺ exchange in cells, and are thus useful for the treatment and/or prevention of cardiovascular, cerebrovascular, and renal disease, arteriosclerosis, shock, etc. For example, condensation of guanidine-HCl with Me 3-(benzofuran-4-yl)benzoate in DMF in the presence of NaOMe, and workup and salification of the product, gave title compound II as its methanesulfonate salt. In a test for inhibition of Na propionate-induced swelling of thymocytes in vitro (measure of Na⁺/H⁺ exchanger activation), an exemplary compound had Ki of < 1.0 + 10⁻⁷.

ACCESSION NUMBER: 1996:365475 HCAPLUS
 DOCUMENT NUMBER: 125:33332
 TITLE: Benzylguanidine derivatives as medicaments inhibiting cellular Na⁺/H⁺ exchange.
 INVENTOR(S): Kuno, Atsushi; Mizuno, Hiroaki; Yamasaki, Kumi; Inoue, Yoshikazu
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604241	A2	19960215	WO 1995-JP1479	19950725
WO 9604241	A3	19960620		
W: AU, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, EA, GR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LA, MD, MG, MN, MW, MY, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SC, SD, SG, SI, SK, SL, SM, SN, TD, TG				
ZA 9506119	A	19960306	ZA 1995-6119	19950721
CA 2196763	AA	19960215	CA 1995-2196763	19950725

L8 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 06 Oct 1995
 GI



AB The N-benzylguanidine derivs. or N-(heteroaroyl)guanidine derivs. I (X, Y, Z = nitrogen, methine; R2 = H, aryl, etc.; R3 = H, alkoxy, hydroxy, etc.) and pharmaceutically acceptable salts thereof were disclosed as pharmaceuticals. I inhibit the sodium/hydrogen exchange in cells and are hence useful for the treatment of cardiovascular diseases, cerebrovascular diseases, renal diseases, arteriosclerosis or shock. A claimed example compound is N-[3-(1H-pyrrol-1-yl)benzoyl]guanidine [i.e., N-(aminoininomethyl)-3-(1H-pyrrol-1-yl)benzamide] (II).

ACCESSION NUMBER: 1995:835463 HCAPLUS
 DOCUMENT NUMBER: 123:256771
 TITLE: Guanidine derivatives as inhibitors of Na⁺/H⁺ exchange in cells
 INVENTOR(S): Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki; Yamasaki, Kumi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426709	A1	19941124	WO 1994-JP786	19940512
W: AU, CA, CN, HU, JP, KR, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
TV 393487	B	20000611	TV 1994-83104223	19940510
CA 2163004	AA	19941124	CA 1994-2163004	19940512
AU 9466912	A1	19941212	AU 1994-66912	19940512
AU 685457	B2	19980122		
HU 70206	A2	19950928	HU 1994-3233	19940512
EP 699185	A1	19960306	EP 1994-914623	19940512
EP 699185	B1	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1123545	A	19960529	CN 1994-192121	19940512
CN 1080257	B	20020306		
JP 08511243	T2	19961126	JP 1994-525245	19940512
RU 2141946	C1	19991127	RU 1995-122558	19940512
AT 205191	E	20010915	AT 1994-914623	19940512
ES 2159558	T3	20011016	ES 1994-914623	19940512
FR 699185	T	20020130	PT 1994-914623	19940512
ZA 9403388	A	19950123	ZA 1994-1388	19940517
US 5824691	A	19981020	US 1995-532804	19951109
GR 3036549	T3	20011231	GR 2001-401402	20010906

L8 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AU 9529916 A1 19960304 AU 1995-29916 19950725
 AU 697748 B2 19981015
 EP 773927 A2 19970521 EP 1995-926026 19950725
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
 CN 1158606 A 19970903 CN 1995-195299 19950725
 CN 1070173 B 20010829
 JP 10503770 T2 19980407 JP 1995-506385 19950725
 JP 3473023 B2 20031202 JP 1996-506385 19950725
 TW 426658 B 20010321 TW 1995-84108031 19950802
 BR 9502471 A 19960521 BR 1995-2471 19950804
 US 5968985 A 19991019 US 1997-776385 19970203
 GB 1994-15852 A 19940805
 GB 1994-22830 A 19941011
 GB 1995-5231 A 19950315
 WO 1995-JP1479 W 19950725

PRIORITY APPL. INFO.:


OTHER SOURCE(S): MARPAT 125:33332
 IT 177732-02-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzylguanidine derivs. as inhibitors of cellular Na⁺/H⁺ exchange)

RN 177732-02-4 HCAPLUS
 CN Benzamide, N-(aminoininomethyl)-3-(1-phenylethenyl)-, monomethanesulfonate (SCI) (CA INDEX NAME)

CH 1

CRN 177732-01-3
 CHF C16 H15 N3 O



CH 2

CRN 75-75-2
 CHF C H4 O3 S




L8 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PRIORITY APPL. INFO.: GB 1993-10074 A 19930517
 GB 1993-25268 A 19931210
 WO 1994-JP786 W 19940512

OTHER SOURCE(S): MARPAT 123:256771

IT 168621-27-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)
 RN 168621-27-0 HCAPLUS
 CN Benzamide, N-(aminoininomethyl)-3-benzoyl-, monomethanesulfonate (SCI) (CA INDEX NAME)

CH 1

CRN 168621-26-9
 CHF C15 H13 N3 O2




CH 2

CRN 75-75-2
 CHF C H4 O3 S



L8 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STM
 ED Entered STN: 21 Mar 1995
 GI




AB Title compds. (I; R1, R2, R3 = H, F, Cl, Br, iodo, alkyl; 1 of R1-R3 = N3, cyano, Oh, alkoxy, etc.), were prepared as inhibitors of the cellular sodium-proton antiporter (no data). Thus, 3,5-dichlorobenzoic acid was stirred with carbonyldiimidazole and then guanidine in THF followed by salification to give 3,5-dichlorobenzoylguanidine hydrochloride.

ACCESSION NUMBER: 1995:426566 HCAPLUS
 DOCUMENT NUMBER: 122:187136
 TITLE: Preparation of substituted benzoylguanidines as inhibitors of cellular Na⁺/H⁺ exchange
 INVENTOR(S): Lang, Hans-Jochen; Weichert, Andreas; Kleemann, Heinz-Werner; Schwark, Jan-Robert; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 18
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 612723	A1	19940831	EP 1994-102322	19940216
EP 612723	B1	19970827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 157351	E	19970915	AT 1994-102322	19940216
ES 2107698	T3	19971201	ES 1994-102322	19940216
FI 9400756	A	19940821	FI 1994-756	19940217
FI 114467	B1	20041029		
IL 108697	A1	20000716	IL 1994-108697	19940217
CA 2115967	AA	19940821	CA 1994-2115967	19940218
NO 9400563	A	19940822	NO 1994-563	19940218
AU 9455229	A1	19940825	AU 1994-55229	19940218
AU 668265	B2	19960426		
ZA 9401119	A	19940830	ZA 1994-1119	19940218
JP 06256291	A2	19940913	JP 1994-20762	19940218
JP 3554352	B2	20040818		
HU 70535	A2	19951030	HU 1994-466	19940218
HU 218915	B	20001228		
TW 420659	B	20010201	TW 1994-93102858	19940401
US 586610	A	19990202	US 1996-683141	19960718
JP 2004189755	A2	20040708	JP 2004-87016	20040324
PRIORITY APPLN. INFO.:			DE 1993-4305250	A 19930220

L8 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STM
 ED Entered STN: 26 Nov 1994
 GI



AB Title compds. (I; R1 = H, halo, CF3, cyano, alkylsulfonyl, etc.; R2 = OR10, NHR10, CHR10R12, CR12R13OR131, COCH2R14, etc.; R3 = H, Me, cyano, CF3, F, Cl, etc.; R10 = CH2[CH(OH)]qCH2OH, (CH2)pO(CH2CH2O)nMe, etc.; R12,R13,R131 = H, alkyl; n,p = 0-2; q = 0-5) were prepared as cardiovascular agents (no data). Thus, 4,3-R2(MeO2S)C6H3CO2Me (II; R2 = Et) was oxidized to II (R2 = MeCO) which was condensed with Me2Zn to give II (R2 = HOCMe2). The latter was refluxed with HN=C(NH2)2 to give, after acidification, I.HCl (R1 = H, R2 = HOCMe2, R3 = SO2Me).


ACCESSION NUMBER: 1994:655423 HCAPLUS
 DOCUMENT NUMBER: 121:255423
 TITLE: Preparation of N-benzoylguanidines as cardiovascular agents
 INVENTOR(S): Weichert, Andreas; Lang, Hans-Jochen; Kleemann, Heinz-Werner; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602522	A1	19940622	EP 1993-119781	19931208
EP 602522	B1	19960529		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 138646	E	19960615	AT 1993-119781	19931208
ES 2087637	T3	19960716	ES 1993-119781	19931208
FI 9305577	A	19940616	FI 1993-5577	19931213
FI 115049	B1	20050228		
AU 9352490	A1	19940630	AU 1993-52490	19931213
AU 663425	B2	19951005		
CA 2111385	AA	19940616	CA 1993-2111385	19931214
NO 9304605	A	19940616	NO 1993-4605	19931214
JP 06234727	A2	19940823	JP 1993-313040	19931214
JP 3545793	B2	20040721		
HU 70427	A2	19951030	HU 1993-3595	19931215
HU 220224	B	20011128		
US 5670544	A	19970923	US 1995-451310	19950526
PRIORITY APPLN. INFO.:			DE 1992-424192	A 19921215
			US 1993-165667	B1 19931213
			US 1994-337237	B1 19941104

OTHER SOURCE(S): MARPAT 121:255423
 IT 158607-77-3P


L8 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 JP 1994-20762 A3 19940218
 US 1994-198812 B1 19940218
 US 1995-391272 B1 19950221

OTHER SOURCE(S): MARPAT 122:187136
 IT 161621-81-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted benzoylguanidines as inhibitors of cellular Na⁺/H⁺ exchange)
 RN 161621-81-4 HCAPLUS
 CN Benzamide, N-(aminoinomethyl)-4-(phenylethynyl)-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L8 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as cardiovascular agent)
 RN 158607-77-3 HCAPLUS
 CN Benzamide, N-(aminoinomethyl)-3-(methylsulfonyl)-4-(phenylacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 20 Aug 1994
 GI



AB Title compds. I (R1 = R4SO_m, R5RGNSO2 wherein R4, R5 = C1-8 alkyl, C3-6 alkenyl, etc.; m = 0-2, R5 = also H, R6 = H, C1-4 alkyl, etc.; R2 = H, C5-8 alkyl, (substituted) Ph, R12C:C wherein R12 = (substituted) Ph, R15R14N wherein R14, R15 = H, C1-4 alkyl, C1-9 (substituted) heteroaryl, C3-8 cycloalkyl, etc.; R3 = groups as defined for R2), or a salt thereof, are prepared I are suitable as antiarrhythmics (data given) treatment or prophylaxis of cardiac infarct, angina pectoris, heart ischemia, etc. (no data). 3-(Methylsulfonyl)-4-phenylbenzoic acid (preparation given) in THF was treated with carbonyldiimidazole followed by guanidine to give I (R1 = MeSO2, R2 = Ph, R3 = H) (II). The antiarrhythmic effect was demonstrated with II by inhibition of Na⁺/H⁺ exchanger of rabbit erythrocytes with IC50 2-3 + 10-6.

ACCESSION NUMBER: 1994:482737 HCAPLUS
 DOCUMENT NUMBER: 121:82737
 TITLE: 3,4,5-substituted benzoylguanidines, process for their preparation, and their use as medicaments
 INVENTOR(S): Weichert, Andreas; Lang, Hans-Jochen; Scholz, Wolfgang; Albus, Udo; Lang, Florian
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Can. Pat. Appl., 34 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2099445	AA	19940102	CA 1993-2099445	19930630
IL 106157	A1	19991130	IL 1993-106157	19930628
FI 113367	B1	20040415	FI 1993-2998	19930629
AU 9341635	A1	19940106	AU 1993-41635	19930630
AU 658309	B2	19950406		
ZA 9304719	A	19940125	ZA 1993-4719	19930630
JP 06116230	A2	19940426	JP 1993-159886	19930630
JP 3490739	B2	20040126		
US 5693672	A	19971202	US 1995-451309	19950526

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 121:82737


L8 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 154117-55-2P 154117-57-4P 156267-44-6P
 156267-45-7P 156267-48-0P 156267-50-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of, as drug)
 RN 154117-55-2 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 154117-57-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 156267-44-6 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethynyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 156267-45-7 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethynyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 156267-48-0 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 156267-50-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L8 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



not ortho.

103 - Positive Isomer -

L8 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 14 May 1994
 GI




AB Title compds. (I; R1 = R4SOO-2, R5R6HSO2; R2, R3 = H, alkyl, CH=CHPh, C.tplbond.CPh, etc.; R4, R5 = alk(en)yl, phenylalkyl, etc.) were prepared. Thus, 4,3-Br(MeO2S)C6H3CO2Me was condensed with cyclopentylzinc chloride and the product converted to I.HCl (R1 = SO2Me, R2 = cyclopentyl, R3 = H) which had IC50 of 1x10-7M for inhibition of the rabbit erythrocyte Na+/H+-exchanger in vitro.

ACCESSION NUMBER: 1994:244385 HCAPLUS
 DOCUMENT NUMBER: 120:244385
 TITLE: Preparation of benzoylguanidines as proton-sodium exchange inhibitors
 INVENTOR(S): Weichert, Andreas; Lang, Hans Jochen; Scholz, Wolfgang; Albus, Udo; Lang, Florian
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 577024	A1	19940105	EP 1993-110195	19930625
EP 577024	B1	19961016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 144248	E	19961115	AT 1993-110195	19930625
ES 2092729	T3	19961201	ES 1993-110195	19930625
NO 9302392	A	19940103	NO 1993-2392	19930630
NO 179673	B	19960819		
NO 179673	C	19961127		
ZA 9304719	A	19940125	ZA 1993-4719	19930630
US 5693672	A	19971202	US 1995-451309	19950526
PRIORITY APPLN. INFO.:			DE 1992-4221594	A 19920701
			DE 1992-4224107	A 19920722
			DE 1992-4224319	A 19921228
			DE 1992-4244319	A 19921228
			US 1993-83576	B1 19930630
			US 1994-303006	B1 19940908


OTHER SOURCE(S): MARPAT 120:244385
 IT 154117-53-OP 154117-55-2P 154117-57-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as proton-sodium exchange inhibitor)
 RN 154117-53-0 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethenyl)-,

L8 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

L8 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 154117-55-2 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 154117-57-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 12 May 1984
 AB Mixed salts of nitrocarboxyhydroxybenzene produced by reaction of nitrated salicylic acid or nitrated alkylene disalicylic acid (where the alkylene is a C1-3 bridge), an amine, and an alkali metal lower alcoholate give combustion catalysts for NH4NO3-based propellants which ensure smooth even burning and produce a min. amount of smoke and ash. Typical catalysts used to an extent of 1-7% are produced from 3,5-dinitro-1-guanidiniumcarboxy-2-sodium phenolate prepared from 3,5-dinitrosalicylic acid, guanidine, and NaOMe and ethylenediaminebis(carboxy-3,5-dinitro-2-sodium phenylate) prepared from ethylenediamine and 2 moles each of 3,5-dinitrosalicylic acid and NaOMe. In propellant compns., most conventional additives may also be present. Thus, a propellant composition was prepared from NH4NO3 (30-80 mesh) 64.62, cellulose acetate 9.15, tri-Et citrate 10.15, dinitrophenoxymethanol 9.30, C 3.60, graphite 0.05, N-phenylmorpholine 1.25, and 5,5'-methylenebis(3,3'-dinitro-1,1'-guanidiniumcarboxy-2,2'-sodium phenylate) 1.88%, burning rate 0.062 in./sec., n 0.487, op 0.075, kk 0.148, in which n = pressure exponent, op = temperature coefficient at constant pressure, and kk = temperature coefficient at constant nozzle throat area and constant burning surface area. A similar composition catalyzed with the usual Na barbiturate showed corresponding values of 0.074, 0.63, 0.09, and 0.24, resp., proving the superiority of the new catalysts.

ACCESSION NUMBER: 1969:79651 HCAPLUS
 DOCUMENT NUMBER: 70:79651
 TITLE: Amine addition products of nitroaminocarboxy alkali metal phenolates for use as propellant combustion catalysts
 INVENTOR(S): Henderson, Lionel A.
 PATENT ASSIGNEE(S): Standard Oil Co.
 SOURCE: U.S., 4 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3420874	A	19690107	US 1962-227048	19620928
PRIORITY APPLN. INFO.:			US 1962-227048	A 19620928
IT 13081-08-8				
RL: CAT (Catalyst use); USES (Uses)				
(catalysts, for combustion of propellants)				
RN 13081-08-8 HCAPLUS				
CN Salicylanide, 5,5'-methylenebis(N-amidino-3-nitro-, disodium salt (8CI) (CA INDEX NAME)				



● 2 Na

L8 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L8 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN


ED Entered STN: 22 Apr 2001

AB Comps. comprising (by weight) about 0.1-15% nitroaminocarboxyalkali metal phenolate (e.g. 2,3,5-NaO(O2N)2C6H2CO2H. (H2N)2C=NH (I), N,N'-piperazinobis(1-carboxy-3,5-dinitro-2-sodium phenolate), or ethylenediaminebis(1-carboxy-3,5-dinitro-2-sodium phenolate), or 5,5-methylenebis(3-nitro-1-guanidiniumcarboxy-2-sodium phenolate) as combustion catalyst, 10-40% oxidizable organic binder material (cellulose ester of a C2-4 alkanolic acid, and a plasticizer) and 60-80% NH4NO3, have superior ignitability characteristics at even the lowest atmos. temps. and show smooth, uniform burning properties at low burning rates. These comps. with an alkali metal barbiturate added have exceptionally low pressure exponents and simultaneously very good temperature coeffs. Reaction of equal moles guanidine and 3,5-dinitrosalicylic acid in MeOH and addition of the theoretical amount of NaOMe gives I, which ppts. in crystalline form. The other combustion catalysts are similarly prepared. The propellant comps. are prepared by blending the ingredients in a one quart laboratory mixer for 1 hr. at about 212°F., after which the pasty mass is compression-molded into a 0.5-in. thick slab, which is allowed to cool to room temperature. The molded comps. are then sawed into strips for use in Crawford bomb burning rate tests, which are carried out at different pressures to determine the pressure exponents(n). In tests to determine temperature coeffs. at both constant pressure (op) and constant nozzle size (sh) a propellant strand is brought to the desired temperature by storage at that temperature. A composition containing (by weight) 61.00% NH4NO3, 9.79% cellulose acetate (about 55% HOAc equivalent), 11.25% tri-2t acetylcitrate, 9.90% dinitrophenoxymethanol (28% diether), 3.00% C, 2.06% I, 2.00% mono-Na barbiturate, 0.50% N-phenylmorpholine, and 0.50% tolylenediamine; gives a burning rate of 0.070 in./sec. at 1000 psia. and 70°F., with n = 0.466. The temperature coeffs. op and sh are 0.100 and 0.19, resp. The comps. described give much less ash formation at a given burning rate than do other propellants containing organic comps. of alkali metals.

ACCESSION NUMBER: 1966:403390 HCAPLUS
DOCUMENT NUMBER: 65:3390
ORIGINAL REFERENCE NO.: 65:566h, 567a-c, 568a
TITLE: Ammonium nitrate propellants
INVENTOR(S): Henderson, Lionel A.
PATENT ASSIGNEE(S): Standard Oil Co.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3247035		19660419	US	19630627
PRIORITY APPLM. INFO.:				
IT 98144-10-6, Sodium, [methylenebis[(2-(amidinocarbamoyl)-6-nitro-p-phenylene)oxy]]di-			US	19630627
(as combustion catalyst in NH4NO3 propellants)				
RN 98144-10-6 HCAPLUS				
CN Sodium, [methylenebis[(2-(amidinocarbamoyl)-6-nitro-p-phenylene)oxy]]di-				
(7CI) (CA INDEX NAME)				

L8 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 Na

IT 802562-85-2, Salicylamide, 5,5'-methylenebis[N-amidino-3-nitro-
(disodium derivative, as combustion catalyst in NH4NO3 propellants)
RN 802562-85-2 HCAPLUS
CN Salicylamide, 5,5'-methylenebis[N-amidino-3-nitro- (8CI) (CA INDEX NAME)

